Immune checkpoint inhibitor treatment of a first cancer is associated with a decreased incidence of second primary cancer

Heudel, P.; Chabaud, S.; Perol, D.; Flechon, A.; Fayette, J.; Combemale, P.; Tredan, O.; Desseigne, F.; de la Fouchardiere, C.; Boyle, H.; Perol, M.; Bachelot, T.; Cassier, P.; Avrillon, V.; Terret, C.; Michallet, A.-S.; Neidhardt-Berard, E.-M.; Nicolas-Virelizier, E.; Dufresne, A.; Belhabri, A.; Brahmi, M.; Lebras, L.; Nicolini, F.; Sarabi, M.; Rey, P.; Bonneville-Levard, A.; Rochefort, P.; Provensal, A.-M.; Eberst, L.; Assaad, S.; Swalduz, A.; Saintigny, P.; Toussaint, P.; Guillermin, Y.; Castets, M.; Coutzac, C.; Meeus, P.; Dupré, A.; Durand, T.; Crochet, H.; Fervers, B.; Gomez, F.; Rivoire, M.; Gregoire, V.; Claude, L.; Chassagne-Clement, C.; Pilleul, F.; Mognetti, T.; Russias, B.; Soubirou, J.-L.; Lasset, C.; Chvetzoff, G.; Mehlen, P.; Beaupère, S.; Zrounba, P.; Ray-Coquard, I.; Blay, J.-Y.

Published in

Esmo Open, Esmo Open, 1(6), p. 100044, 2021

DOI: 10.1016/j.esmoop.2020.100044

Tools

Export citation

Search in Google Scholar

Immune checkpoint inhibitor treatment of a first cancer is associated with a decreased incidence of second primary cancer

Journal article published in 2021 by P. Heudel, S. Chabaud, D. Perol, A. Flechon, J. Fayette, P. Combemale, O. Tredan, F. Desseigne, C. de la Fouchardiere

, H. Boyle, M. Perol, T. Bachelot, P. Cassier, V. Avrillon, C. Terret and other authors.

This paper was not found in any repository; the policy of its publisher is unknown or unclear.

Full text: Unavailable

Preprint: policy unknown

Upload

Postprint: policy unknown

Upload

Published version: policy unknown

Upload

Policy details

Data provided by

Published in

Links

Tools

Immune checkpoint inhibitor treatment of a first cancer is associated with a decreased incidence of second primary cancer